Bio Ring Diagnostics

Project Information

Bio Ring Diagnostics

Grant agreement ID: 866899

DOI

10.3030/866899

Project closed

EC signature date 11 May 2019

Start date 1 June 2019

End date 30 November 2019

Funded under

• INDUSTRIAL LEADERSHIP - Innovation In SMEs

Total cost

€ 71 429,00

EU contribution

€ 50 000,00

Coordinated by

DELTA DIAGNOSTICS BV
Netherlands

Periodic Reporting for period 1 - Bio Ring Diagnostics (Bio Ring Diagnostics)

Reporting period: 2019-06-01 to 2019-11-30

Summary of the context and overall objectives of the project

Delta Diagnostics develops biosensors based on integrated optical chips for various applications in life-science research and point-of-care diagnostics. There is a growing need for affordable label-free biosensing instruments for research, as well as novel sensitive and highly-multiplexed point-of-care diagnostic tests. We aim to make sensitive, multiplexed, label-free biosensing accessible to all. During the SMEi phase 1 project, the feasibility of our business idea was determined by reaching the following objectives:
• Objective 1: Market analysis and business plan
• Objective 2: Description of technical concepts/ design of principal technology platform and architecture for the MVP.
• Objective 3: Partner search
• Objective 4: Commercial and legal strategy

Work performed from the beginning of the project to the end of the period covered by the report and main results achieved so far

We have performed a thorough market analysis and had a large number of meetings with potential customers, suppliers and other stakeholders. We drafted a business plan for the development and marketing of our first and subsequent products. Research on the technical feasibility was performed, leading to a highly innovative instrument architecture and a functioning prototype. The economic feasibility was confirmed, a.o. via a bill-of material analysis and development of a pricing strategy.

Progress beyond the state of the art and expected potential impact (including the socio-economic impact and the wider societal implications of the project so far)

Conclusions of the SMEi feasibility study:
- There is an unmet need for label-free detection technology for point of care diagnostics. Current label-free technology is not suitable for use outside the lab.
- The fact that with our technology we can make a smooth transition from lab-developed assay to point-of-care test is highly valued by many potential customers.
- The developed strategy is commercially viable.
- Technical viability has been proven through the realization of a prototype, based in a novel instrument architecture.
- The results of the SMEi feasibility study have helped Delta Diagnostics to secure funding for a validation project in which the technology will be internally and externally validated.
- As result of the positive outcome of the SMEi feasibility study, we intent to apply for SMEi phase 2 funding to advance from prototype to final product.

rings.jpg